首页> 外文期刊>BMC Nephrology >Associations of GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients
【24h】

Associations of GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients

机译:GSTM1 * 0和GSTA1 * A基因型与血液透析患者心血管死亡风险的相关性

获取原文
           

摘要

Background The presence of glutathione transferase (GST) M1 null genotype (GSTM1-null) in end-stage renal disease (ESRD) patients is associated with lower overall survival rate in comparison to those with GSTM1-active variants. We examined association between GSTM1 and GSTT1 deletion polymorphisms as well as SNPs in GSTA1/rs3957357 and GSTP1/rs1695 genes with overall and cause-specific cardiovascular mortality in ESRD patients. Methods Total of 199 patients undergoing hemodialysis were included in the study. Median value of time elapsed from dialysis initiation until the death, or the end of follow-up was 8?±?5 years. The effect of GSTM1, GSTT1, GSTP1 and GSTA1 gene polymorphisms on predicting overall and specific cardiovascular outcomes (myocardial infarction, MI or stroke) was analyzed using Cox regression model, and differences in survival were determined by Kaplan-Meier. Results GSTM1-null genotype in ESRD patients was found to be independent predictor of overall and cardiovascular mortality. However, after false discovery rate and Bonferroni corrections this effect was lost. The borderline effect modification by wild-type GSTA1*A/*A genotype on associations between GSTM1-null and analyzed outcomes was found only for death from stroke. Homozygous carriers of combined GSTM1*0/GSTA1*A genotype exhibited significantly shorter time to death of stroke or MI in comparison with carriers of either GSTM1-active or at least one GSTA1*B gene variant. The best survival rate regarding cardiovascular outcome was found for ESRD patients with combined GSTM1-active and mutant GSTA1*B/*B genotype. Conclusions Combined GSTM1*0/GSTA1*A genotypes might be considered as genetic markers for cardiovascular death risk in ESRD patients, which may permit targeting of preventive and early intervention.
机译:背景终末期肾病(ESRD)患者中存在谷胱甘肽转移酶(GST)M1无效基因型(GSTM1-null),与具有GSTM1活性变体的患者相比,其总生存率较低。我们检查了GSTM1 / GSTT1缺失多态性以及GSTA1 / rs3957357和GSTP1 / rs1695基因中的SNP与ESRD患者总体和特定原因心血管死亡率之间的关联。方法共纳入199例接受血液透析的患者。从开始透析到死亡或随访结束的时间中位数为8±5年。使用Cox回归模型分析了GSTM1,GSTT1,GSTP1和GSTA1基因多态性对预测整体和特定心血管结局(心肌梗塞,MI或中风)的影响,并通过Kaplan-Meier确定了生存差异。结果发现ESRD患者的GSTM1空基因型是整体和心血管死亡率的独立预测因子。但是,在错误发现率和Bonferroni校正之后,此效果消失了。发现野生型GSTA1 * A / * A基因型对GSTM1-null与分析结果之间的关联具有临界作用,仅针对卒中死亡。与具有GSTM1活性或至少一个GSTA1 * B基因变体的载体相比,组合的GSTM1 * 0 / GSTA1 * A基因型的纯合子载体显示出卒中或MI死亡的时间大大缩短。对于合并了GSTM1活性和突变GSTA1 * B / * B基因型的ESRD患者,发现了关于心血管结局的最佳生存率。结论组合的GSTM1 * 0 / GSTA1 * A基因型可被认为是ESRD患者心血管死亡风险的遗传标记,这可能有助于预防和早期干预。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号